MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.ahj.2022.11.013

Медицинская библиотека · American heart journal · 2022

BAlloon expandable vs. SElf expanding transcatheter vaLve for degenerated bioprosthesIs: design and rationale of the BASELINE trial.

Nuis Rutger-Jan, van Belle Eric, Teles Rui, Blackman Daniel, Veulemans Verena, Santos Ignacio Amat, Pilgrim Thomas, Tarantini Giuseppe, Saia Francesco, Iakovou Ioannis, Mascherbauer Julia, Vincent Flavien, Geleijnse Marcel, Sathananthan Janarthanan, Wood David, Makkar Raj, Van Mieghem Nicolas M, BASELINE Investigators

СтатьяПротокол клинического исследованияПеревод пока не подготовлен

Аннотация

BACKGROUND

Surgical aortic valve bioprostheses may degenerate over time and require redo intervention. Transcatheter aortic valve replacement (TAVR) is a less invasive alternative to redo surgery. The BAlloon Expandable vs. SElf Expanding Transcatheter VaLve for Degenerated BioprosthesIs (BASELINE) trial was designed to compare the performance of the balloon-expandable SAPIEN-3 Ultra and the self-expanding EVOLUT PRO+ valve systems in symptomatic patients with a failing surgical bioprosthesis.

METHODS

The BASELINE trial is an investigator-initiated, non-funded, prospective, randomized, open-label, superiority trial enrolling a total of 440 patients in up to 50 sites in 12 countries in Europe and North-America. The primary endpoint is device success at 30-days defined by the Valve Academic Research Consortium-3 Criteria as the composite of technical success, freedom from mortality, freedom for surgery or intervention related to the device or to a major vascular or access-related or cardiac structural complication with an intended performance of the valve (mean gradient <20 mmHg and less than moderate aortic regurgitation). The co-primary endpoint at 1 year is defined as the composite of all-cause death, disabling stroke, rehospitalization for heart failure or valve related problems. Independent Core Laboratories will conduct uniform analyses of echocardiography (pre-, post-, 1-year post-procedure), multi-sliced computed tomography (pre-, and if available post-procedure) and cine-fluoroscopy studies.

CONCLUSIONS

The BASELINE trial is a head-to-head comparative trial investigating the 2 most used contemporary transcatheter heart valves for the treatment of a failing surgical aortic bioprosthesis. (ClinicalTrials.gov number NCT04843072).

Для цитирования: Nuis Rutger-Jan, van Belle Eric, Teles Rui, Blackman Daniel, Veulemans Verena, Santos Ignacio Amat, Pilgrim Thomas, Tarantini Giuseppe, Saia Francesco, Iakovou Ioannis, Mascherbauer Julia, Vincent Flavien, Geleijnse Marcel, Sathananthan Janarthanan, Wood David, Makkar Raj, Van Mieghem Nicolas M, BASELINE Investigators. BAlloon expandable vs. SElf expanding transcatheter vaLve for degenerated bioprosthesIs: design and rationale of the BASELINE trial.. American heart journal. 2022. DOI: 10.1016/j.ahj.2022.11.013.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.